Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Google Secures Pentagon AI Deal for Classified Projects 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
TUCSON, Ariz., May 01, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 first quarter results after market close on Monday, May 15, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, May 15 to discuss these results and answer questions.
Individuals interested in listening to the conference call may do so by dialing (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers (conference ID: 13619211), or from the webcast on the “Investors” section of the Company’s website at: www.htgmolecular.com. The webcast will be available on the Company’s website for 90 days following the completion of the call.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: (415) 513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: (520) 547-2827 x130 Email: [email protected]
